Tarsus Pharmaceuticals Q3 EPS $(0.30) Beats $(0.38) Estimate, Sales $118.697M Beat $115.222M Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings BeatsNews
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.38) by 21.88 percent. This is a 50.82 percent increase over losses of $(0.61) per share
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.38) by 21.88 percent. This is a 50.82 percent increase over losses of $(0.61) per share from the same period last year. The company reported quarterly sales of $118.697 million which beat the analyst consensus estimate of $115.222 million by 3.02 percent. This is a 146.68 percent increase over sales of $48.118 million the same period last year.